Ixaka develops proprietary cell and gene therapies which use the inherent therapeutic power of cells to treat and potentially cure disease.
Our therapies work by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Our proprietary technologies offers potentially dramatic improvements across a wide range of serious diseases where current treatment options are poor.
Ixaka’s proprietary technologies: concentrated Multi-Cell Therapies (MCT) and Nano-Particle Therapeutics (NPT), have the potential to treat, and even cure a wide range of serious diseases with a low risk of side effects. These disease applications include cancers degenerative cardiovascular diseases, genetic disorders, neurological and ocular diseases.
Our bioengineered cell therapies are targeted to regenerate tissues, destroy diseased cells or produce beneficial genetic modifications.
Following highly encouraging results from three phase 2 studies, Ixaka initiated a pivotal, placebo-controlled, double-blind, adaptive Phase 3 trials in patients with Rutherford category 5 CLTI and Diabetes Mellitus (DM).
The design of the trial, including the patient population and primary endpoints was developed with our internationally renowned clinical advisors in consultation with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).